TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Daniel Barthelmes, Nguyen Vuong, Vincent Daien, Anna Campain, Richard Walton, Robyn Guymer, Nigel Morlet, Alex P Hunyor, Rohan W Essex, Jennifer J Arnold, Mark C Gillies
Retina | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018
Supported by a grant from the Royal Australian NZ College of Ophthalmologists Eye Foundation (2007-2009) and a grant from the National Health and Medical Research Council, Australia (NHMRC 2010-2012).M. C. Gillies is a Sydney Medical Foundation Fellow and is supported by an NHMRC practitioner fellowship, and R. Guymer is supported by a NHMRC Principal research fellowship. D. Barthelmes was supported by the Walter and Gertrud Siegenthaler Foundation Zurich, Switzerland and the Swiss National Foundation. Funding was also provided by Novartis and Bayer. These supporting organizations had no role in the design or conduct of the research. M. C. Gillies and R. Guymer are members of advisory boards for Novartis and Bayer. D. Barthelmes received research grants from Novartis and Bayer. V. Daien received travel grants from Novartis and Bayer. None of the other authors have no any conflicting interests to disclose.